BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Macarulla Mercadé T, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial. Pancreas 2020;49:62-75. [PMID: 31856081 DOI: 10.1097/MPA.0000000000001455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ali N, Srivastava N. Recent Advancements for the Management of Pancreatic Cancer: Current Insights. CCTR 2021;17:267-82. [DOI: 10.2174/1573394717666210625153256] [Reference Citation Analysis]
2 Zaibet S, Hautefeuille V, Auclin E, Lièvre A, Tougeron D, Sarabi M, Gilabert M, Wasselin J, Edeline J, Artru P, Bechade D, Morin C, Ducoulombier A, Taieb J, Pernot S. Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. Br J Cancer. [DOI: 10.1038/s41416-022-01713-w] [Reference Citation Analysis]
3 Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, Furukawa M, Okusaka T, Kawabe K, Furuse J, Komatsu Y, Ishii H, Sato A, Shimizu S, Chugh P, Tang R, Ioka T. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Cancer Med 2020;9:9396-408. [PMID: 33099898 DOI: 10.1002/cam4.3558] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Frampton JE. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. Drugs 2020;80:1007-18. [PMID: 32557396 DOI: 10.1007/s40265-020-01336-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
5 Thakur G, Kumar R, Kim SB, Lee SY, Lee SL, Rho GJ. Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma. Biomedicines 2021;9:178. [PMID: 33670230 DOI: 10.3390/biomedicines9020178] [Reference Citation Analysis]
6 Assi HA, Shikdar S, Alhyari L, Aljumaily R. Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer. Pancreas 2020;49:e95-6. [PMID: 33003100 DOI: 10.1097/MPA.0000000000001649] [Reference Citation Analysis]